The mixed Q4 financial results for Recursion Pharmaceuticals suggest that while there may have been some positive aspects, the negative outcomes likely outweighed them in investors' eyes, leading to a decrease in stock price. This reaction is typical when companies report mixed or uncertain financial performance, as investors prefer clear positive indicators of growth and profitability.